RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Analysts

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) have been given an average rating of “Hold” by the thirteen research firms that are currently covering the company, MarketBeat reports. Nine analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $24.67.

Several research firms have weighed in on RAPT. JPMorgan Chase & Co. lowered their price target on RAPT Therapeutics from $15.00 to $13.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 27th. HC Wainwright reissued a “neutral” rating on shares of RAPT Therapeutics in a report on Wednesday, April 10th. Guggenheim lowered RAPT Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 10th. Barclays lowered RAPT Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $13.00 to $4.00 in a report on Friday, May 10th. Finally, Wolfe Research reissued a “peer perform” rating on shares of RAPT Therapeutics in a report on Tuesday, May 14th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in RAPT Therapeutics by 21.2% in the 1st quarter. Vanguard Group Inc. now owns 2,492,850 shares of the company’s stock valued at $22,386,000 after buying an additional 436,629 shares in the last quarter. Perceptive Advisors LLC grew its holdings in RAPT Therapeutics by 11.4% in the 4th quarter. Perceptive Advisors LLC now owns 2,139,950 shares of the company’s stock valued at $53,178,000 after buying an additional 219,292 shares in the last quarter. Kingdon Capital Management L.L.C. grew its holdings in RAPT Therapeutics by 55.3% in the 1st quarter. Kingdon Capital Management L.L.C. now owns 1,500,000 shares of the company’s stock valued at $13,470,000 after buying an additional 534,172 shares in the last quarter. Redmile Group LLC grew its holdings in RAPT Therapeutics by 80.6% in the 1st quarter. Redmile Group LLC now owns 662,398 shares of the company’s stock valued at $5,948,000 after buying an additional 295,622 shares in the last quarter. Finally, TimesSquare Capital Management LLC acquired a new position in RAPT Therapeutics in the 4th quarter valued at $12,533,000. 99.09% of the stock is owned by institutional investors and hedge funds.

RAPT Therapeutics Stock Down 3.1 %

NASDAQ:RAPT opened at $3.64 on Friday. The firm has a market capitalization of $126.86 million, a price-to-earnings ratio of -1.18 and a beta of 0.36. RAPT Therapeutics has a twelve month low of $2.61 and a twelve month high of $27.35. The stock’s 50 day moving average price is $3.65 and its two-hundred day moving average price is $10.88.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.01). As a group, analysts anticipate that RAPT Therapeutics will post -2.93 earnings per share for the current year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.